KA
BIIB icon

Kercheville Advisors’s Biogen BIIB Stock Holding History

Kercheville Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-960
Closed -$272K – 119
2021
Q3 		$272K Sell
960
-200
-17% -$65.5K 0.13% 87
2021
Q2 		$402K Sell
1,160
-65
-5% -$19.7K 0.19% 78
2021
Q1 		$344K Buy
+1,225
New +$330K 0.17% 85

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Kercheville Advisors's BIIB Position: Q4 2021 in Review

Kercheville Advisors sold out of Biogen (BIIB) in Q4 2021, closing a stake of 960 shares — an estimated $272K sold.

Kercheville Advisors first reported a position in BIIB in Q1 2021 and held it in 3 quarters. The position peaked at $402K in Q2 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

  • Kercheville Advisors reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
  • Kercheville Advisors sold 960 Biogen shares in Q4 2021, an estimated $272K.
  • Kercheville Advisors first reported a position in Biogen in Q1 2021 and held it in 3 quarters.
  • Kercheville Advisors's Biogen position peaked at $402K in Q2 2021.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Kercheville Advisors's 13F filing for Q4 2021, filed 26 Jan 2022.